ImpediMed Management

Management criteria checks 0/4

ImpediMed's CEO is Parmjot Bains, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.001% of the company’s shares, worth A$2.03K. The average tenure of the management team and the board of directors is 0.7 years and 0.6 years respectively.

Key information

Parmjot Bains

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.001%
Management average tenure	less than a year
Board average tenure	less than a year

Recent management updates

Recent updates

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Feb 01

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Aug 25

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Apr 06

Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

Feb 12

ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

Jan 08

How Does ImpediMed's (ASX:IPD) CEO Salary Compare to Peers?

Nov 25

CEO

Parmjot Bains

less than a year

Tenure

Dr. Parmjot Bains, M.D. serves as Managing Director at ImpediMed Limited from January 08, 2023 and serves as its Interim CEO and Director from 2024 and served as its Chief Executive Officer since and until...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Shashi Tripathi	Chief Operating Officer	1.4yrs	AU$945.99k	0.14% A$ 257.2k
Parmjot Bains	MD, Interim CEO & Director	less than a year	no data	0.0011% A$ 2.0k
McGregor Grant	Interim CFO & Executive Director	less than a year	no data	0.10% A$ 193.2k
Dennis Schlaht	Senior Vice President of R&D and Technology	no data	AU$704.20k	no data
Lisa Prom	Vice President of Sales	no data	no data	no data
Joann Yao	Chief Strategy Officer	less than a year	no data	no data
Steven Chen	Chief Medical Center	less than a year	no data	no data
Leanne Ralph	Company Secretary	9.3yrs	no data	no data
Walton Taylor	Medical Director	14.1yrs	no data	no data

0.7yrs

Average Tenure

Experienced Management: IPD's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Parmjot Bains	MD, Interim CEO & Director	less than a year	no data	0.0011% A$ 2.0k
McGregor Grant	Interim CFO & Executive Director	less than a year	no data	0.10% A$ 193.2k
Christine Emmanuel-Donnelly	Independent Non-Executive Chair	less than a year	no data	0.014% A$ 27.3k
Andrew Grant	Independent Non-Executive Director	less than a year	no data	0.015% A$ 28.2k
Janelle Delaney	Independent Non-Executive Director	less than a year	no data	0.16% A$ 309.8k

0.6yrs

Average Tenure

Experienced Board: IPD's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.

ImpediMed Management

Management criteria checks 0/4

Key information

Recent management updates

Independent Non-Executive Director recently bought AU$100k worth of stock

Independent Non-Executive Director recently bought AU$90k worth of stock

High number of new and inexperienced directors

Independent Non-Executive Director recently bought AU$135k worth of stock

ImpediMed Limited Announces CFO Changes

ImpediMed Limited, Annual General Meeting, Nov 30, 2023

Recent updates

Price target decreased by 9.6% to AU$0.18

ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Independent Non-Executive Director recently bought AU$100k worth of stock

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates decrease by 13%

Independent Non-Executive Director recently bought AU$90k worth of stock

Price target decreased by 12% to AU$0.19

No longer forecast to breakeven

High number of new and inexperienced directors

New minor risk - Share price stability

ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024

Independent Non-Executive Director recently bought AU$135k worth of stock

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Consensus revenue estimates decrease by 20%

ImpediMed Limited Announces CFO Changes

Price target decreased by 16% to AU$0.23

Price target increased by 21% to AU$0.27

ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023

ImpediMed Limited, Annual General Meeting, Nov 30, 2023

High number of new directors

ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer

Consensus revenue estimates decrease by 23%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

ImpediMed Limited, Annual General Meeting, Sep 28, 2023

Price target increased by 27% to AU$0.21

ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

ImpediMed Limited Appoints Daniel Sharp as Director

Executive Director recently bought AU$144k worth of stock

Independent Non-Executive Chairman recently bought AU$82k worth of stock

No longer forecast to breakeven

MD, CEO & Director recently bought AU$52k worth of stock

MD, CEO & Director recently bought AU$54k worth of stock

Price target increased by 25% to AU$0.18

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

MD, CEO & Director recently bought AU$64k worth of stock

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

Price target decreased by 7.7% to AU$0.17

ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023

ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Impedimed Limited Announces CEO Changes

ImpediMed Limited Announces Management Changes

Less than half of directors are independent

Executive Director & Interim CEO recently bought AU$164k worth of stock

Less than half of directors are independent

ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema

ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022

ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Consensus forecasts updated

Price target decreased to AU$0.18

ImpediMed Limited Announces Board Changes

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ImpediMed Limited, Annual General Meeting, Oct 26, 2022

Price target decreased to AU$0.22

ImpediMed Limited Announces Executive Changes

Less than half of directors are independent

ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform

No longer forecast to breakeven

ImpediMed Limited to Report Q3, 2022 Results on Apr 28, 2022

New Bone Data Showing Strong Correlation Between ImpediMed's SOZO and DXA in Cancer Patients Presented At 39Th Annual Miami Breast Cancer Conference

No longer forecast to breakeven

Consensus revenue estimates fall by 21%

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 24% undervalued

ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-Up